Onkolitik sterile injectable pharmaceutical factory in Turkey is the first FDA approval of MN, due to shipping facilities Yenibosna a ceremony held on Thursday 2 December 2010. MN until 2012 the U.S. will export 10 different oncology drugs and oncology support.
MN Pharmaceuticals Inc. General Manager M. Levent Selamoğlu his speech, the shipping to the U.S. for the first time a Turkish firm through a difficult area such as a global player in oncology, he said. MN is not only for exports to the Turkish pharmaceutical sector is an important step in emphasizing the Selamoğlu said:
"Exported to the U.S. oncology products will carry the first batch of trucks, 87 years ago, placed a strong vision, a very big labor, the goals will and determination is the result of a şaşmayan. U.S. Food and Drug Administration found in the FDA approval of this shipment took place as a result of the Turkish drug cancer drug sector exports to the United States for the first time. a real success for the Turkish pharmaceutical industry which we are proud of this development. Mustafa Nevzat'ın what it can achieve success is a testament to our industry at the global level.
Opened the way many believe the drug company will follow us. "
View Nevzat'ın, turnover of 6 billion dollars in the U.S. and the world's second-largest generic drug company Mylan Inc.. with the field of generic injectable sales, distribution and marketing has a strategic partnership. Mylan Inc., MN Pharmaceuticals in the field of generic injectable business, as well as technology partner in the partnership did. This high-tech and specialized products to be developed in the near future, with the production of Mylan Inc. in MN. a comprehensive co-operation
am in.
Left unattended at the beginning of 2008 Onkolitik Products Manufacturing Unit-IV drug manufacturing plant in determining production standards as a foundation of the world's most important official of the U.S. Food and Drug Administration accepted the FDA (Food and Drug Administration) approved in May 2010 by. In July 2010 the European Medicines Agency approval of the facility so that standards around the world in the field of drug-making that determines the success of the check showing the two institutions at the same time, Turkey was the first onkolitik drug manufacturing facility.
25 million U.S. dollars were invested in the facility onkolitik lyophilized injectable products and docetaxel, idarubisin, irinotecan, fludarabine, oxaliplatin, epirubicin, vinorelbine, carboplatin active ingredient produced in sterile-injectable products. Onkolitik between the plant product portfolio also support the treatment of cancer in chemotherapy-induced nausea / vomiting is used in the treatment of products, products used in the treatment of bone metastases and include immunomodulators. Here, in the near future
onkolitik products produced in the oral. 4 million cans a year in one shift of production at the facility can be made. Meanwhile, nano-technology for the production of cancer drugs in R & D efforts are continuing.
No comments:
Post a Comment